Fig. 5: The 4RBD-Fc antiviral formulation induced more robust systemic and mucosal immunity than the vaccine formulation. | Communications Biology

Fig. 5: The 4RBD-Fc antiviral formulation induced more robust systemic and mucosal immunity than the vaccine formulation.

From: Single-dose infusion of engineered viral receptor binding domain confers rapid and durable protection against viral infection

Fig. 5

A Illustration of the administration protocol in C57BL/6 mice: Mice were given i.n. 4RBD-Fc vaccine or antiviral formulations, with a booster on day 14. The mock group received 20 μg CpG in PBS (n = 5). B Representative flow cytometry plots of RBD+ BRMs (CD45i.v.-CD19+CD38+IgD-RBD-FITC+RBD-PE-Cy7+). Cells that were CD45i.v.-CD19+ were defined as lung-resident B cells. ELISA detection of anti-RBD IgG titer in serum (C) and BAL (D) and anti-RBD IgA in BAL (E). F Neutralization assay of serum at day 28 using SARS-CoV-2 WT pseudovirus, IC50 values are indicated. RBD+ GC B cell counts (G) in mdLN and counts of RBD+ BRMs (H) in lungs at day 28. The percentage of pulmonary T cells responsive to RBD peptide library stimulation, including CD4+ (I) and CD8+ T cells (J). Data are presented as mean ± s.d., symbols denote individual data points collected from mice. The dashed line indicates the limit of detection (LOD). Undetectable values were set to LOD –0.2 log units to distinguish them. Statistical significance was calculated by one-way ANOVA with Dunnett correction.

Back to article page